Neuronetics (STIM) Aktsia Kursus
Neuronetics Kursus
Viimase 9 aasta jooksul kasvas Neuronetics käive 17,8 % aastas ja jõudis 149,16 M USD-ni. Neuronetics netomarginaal −26,1 % on tõusnud võrreldes −56,4 %-ga mõni aasta tagasi. Neuronetics 12 kuu konsensuse hinnasiht on 5,00 USD, umbes üle kurssi 137,0 %. 10 analüütikust 9 soovitab osta — üldine konsensus on Osta.
Neuronetics aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Neuronetics ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Neuronetics aktsia kohta
The business model of Neuronetics Inc. focuses on providing innovative medical technology solutions for patients suffering from psychiatric disorders, particularly major depressive disorder (MDD). As a leading medical device company, Neuronetics specializes in developing and commercializing NeuroStar® Advanced Therapy, an FDA-cleared non-invasive transcranial magnetic stimulation (TMS) system. This breakthrough treatment option offers a safe and effective alternative to traditional antidepressant medications. Neuronetics offers a comprehensive approach, combining their advanced TMS technology with clinical support and patient education. By addressing the unmet needs of individuals with MDD, Neuronetics aims to improve the quality of life for patients and enhance mental health treatment outcomes.
Neuronetics Inc is primarily active in the healthcare industry.
The main competitors of Neuronetics Inc in the market include companies such as MagVenture, BrainsWay, and Fisher Wallace.
Neuronetics Inc is a reputable medical device company founded in 2003. Headquartered in Pennsylvania, the company focuses on developing innovative treatments for psychiatric disorders, specifically major depressive disorder (MDD). Neuronetics Inc is widely recognized for its groundbreaking invention, NeuroStar Advanced Therapy system, which utilizes transcranial magnetic stimulation (TMS) to alleviate depressive symptoms. With a commitment to providing non-invasive and effective solutions, Neuronetics Inc has gained significant recognition within the medical community. Over the years, the company has strived to improve patients' well-being and enhance mental health treatment options, solidifying its position as a leader in the field of neuromodulation therapies.
Neuronetics Inc has achieved significant milestones since its inception. The company introduced the NeuroStar Advanced Therapy, an FDA-cleared transcranial magnetic stimulation (TMS) system, which has revolutionized the treatment of depression. Neuronetics Inc expanded its reach by attaining various regulatory clearances globally, allowing patients worldwide to benefit from TMS therapy. The company also secured multiple strategic partnerships, further enhancing its market presence and advancing the field of neuromodulation. Neuronetics Inc's dedication to research and innovation has led to numerous clinical publications highlighting the effectiveness of NeuroStar TMS therapy. With its relentless pursuit of advancing psychiatric care, Neuronetics Inc continues to make significant strides in improving patient outcomes and quality of life.
Neuronetics Inc is primarily present in the United States.
Neuronetics Inc represents values of innovation, patient-centricity, and continuous improvement. With a corporate philosophy focused on developing advanced solutions for mental health disorders, Neuronetics Inc strives to improve the lives of individuals suffering from depression. The company's NeuroStar Advanced Therapy system, utilizing transcranial magnetic stimulation, is a testament to their commitment to innovation and providing effective treatment options. By placing patients at the center of their efforts, Neuronetics Inc aims to enhance mental health outcomes and restore hope for those in need.
Analüütikud määravad Neuronetics aktsiale keskmiseks hinnasihi 5,00 USD (mediaan: 5,00 USD), mis on +137,0 % viimase hinna suhtes. Konsensus põhineb 10 analüütiku hinnangul.
10 analüütikut hindavad praegu Neuronetics aktsiat: 9 soovitab osta, 1 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Neuronetics teenib tulu 161,83 M USD ja kasumit aktsia kohta −0,33 USD.
Praeguse kursiga kaubeldakse Neuronetics aktsiaga 1,88 EUR (2,11 USD) juures.
Neuronetics aktsia (STIM) on noteeritud 3 börsil, sh: NASDAQ (STIM), Frankfurt (NRC.F), München (NRC.MU).
Neuronetics Inc. is a leading manufacturer of medical devices that help patients with mental disorders such as depression. The company is headquartered in Malvern, Pennsylvania, USA. Neuronetics Inc.'s business model is based on selling devices for Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive method for treating severe depression in patients who have not responded to other treatment methods. The method uses high-intensity magnetic pulses to stimulate the brain, resulting in a reduction of symptoms. The company's core product is the NeuroStar Advanced Therapy System (ATS). The system consists of a TMS device and a specialized treatment chair. The chair can be individually adjusted to meet the patient's needs for optimal treatment. The NeuroStar ATS is the first TMS therapy in the USA to be approved by the Food and Drug Administration (FDA) for use in patients with depression. Neuronetics Inc. distributes its products through a broad sales structure. The company has its own sales representatives who handle the sales and marketing of the products in the USA and Europe. In addition, Neuronetics Inc. collaborates with distribution partners to distribute its products in countries where the company is not directly represented. The company also has a strong research component. Neuronetics Inc. has established a network of clinics and research institutions that participate in clinical studies on TMS therapy. The company also supports independent researchers working on the development of new applications of TMS therapy. Neuronetics Inc. works closely with health insurance companies and private insurers to ensure that its products can be used by as many patients as possible. The company maintains constant contact with healthcare decision-makers and organizes regular conferences and workshops to inform about the possibilities of TMS therapy. In summary, Neuronetics Inc. is an innovative company dedicated to the treatment of patients with severe depression. The company offers a high-quality and safe treatment system that has already been successfully used by many patients. With its broad sales structure and strong research component, Neuronetics Inc. is well positioned to continue to play a leading role in the market for TMS therapy.
oodatav Neuronetics käive on 161,83 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Neuronetics kasum on −22,98 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Neuronetics jaoks on praegu −6,31. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Neuronetics aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Neuronetics jaoks on praegu 0,90. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Neuronetics aktsia jaoks.
Eulpooli kvaliteedinäitaja Neuronetics jaoks on 3/10.
Neuronetics ISIN on US64131A1051. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Neuronetics WKN on A2JPMY. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Neuronetics ticker on STIM. Ticker-sümbol kasutatakse Neuronetics aktsiate kauplemiseks börsil.
Neuronetics aktsia
Neuronetics konkurendid
Neuronetics Börsiticker
Neuronetics FIGI
Kõik teised näitajad ja analüüsid Neuronetics kohta sügavamalt
Meie Neuronetics-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Neuronetics. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: